{"id":"b159300a-3f3d-5215-a325-48cbf0c5cf85","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:octn2-brain","predicate":"decreases_in_recorded_comparison","statement":"Defective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"3e976906-693b-5052-a9f5-525f453e6797","mechanism_event_label":"Defective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.","subject":{"id":"cb4d15e3-bce8-519d-baab-4c3b06931f28","slug":"mouse-slc22a5","display_name":"Mouse carnitine transporter Octn2 / Slc22a5","entity_type_key":"protein"},"object":{"id":"df74510e-f072-50ac-8f09-d38915f98712","slug":"mouse-brain-alcar-uptake","display_name":"Mouse blood-to-brain ALCAR uptake","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"3e976906-693b-5052-a9f5-525f453e6797","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:octn2-brain-event","event_type":"experimental_observation","label":"Defective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.","description":"### octn2-brain\n\nDefective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.\nThe study supports at least partial OCTN2 involvement, not a universal human uptake multiplier or exclusive transporter dependence.\nModel and exposure: Mouse wild-type versus juvenile visceral steatosis model; microdialysis and zero-net-flux analysis.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. | 2003 | https://pubmed.ncbi.nlm.nih.gov/14595704/ | https://doi.org/10.1002/bdd.371 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"cb4d15e3-bce8-519d-baab-4c3b06931f28","slug":"mouse-slc22a5","display_name":"Mouse carnitine transporter Octn2 / Slc22a5","entity_type_key":"protein"},"role":"tested factor","stoichiometry":null,"state_label":"Defective OCTN2 in jvs mice","sequence_order":0,"notes":""},{"entity":{"id":"df74510e-f072-50ac-8f09-d38915f98712","slug":"mouse-brain-alcar-uptake","display_name":"Mouse blood-to-brain ALCAR uptake","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"transported metabolite","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Defective OCTN2 in jvs mice\", \"comparator\": \"Wild-type mice\", \"endpoint\": \"Defective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse wild-type versus juvenile visceral steatosis model; microdialysis and zero-net-flux analysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Defective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. | https://pubmed.ncbi.nlm.nih.gov/14595704/ | https://doi.org/10.1002/bdd.371","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference octn2-brain; The study supports at least partial OCTN2 involvement, not a universal human uptake multiplier or exclusive transporter dependence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"4ef7e639-706c-581f-96ea-b7897fd74f72","evidence_kind":"source_excerpt","locator":"Lines 96-102","start_line":96,"end_line":102,"excerpt":"### octn2-brain\n\nDefective Octn2 reduced initial ALCAR brain uptake and thalamic extracellular ALCAR in jvs mice.\nThe study supports at least partial OCTN2 involvement, not a universal human uptake multiplier or exclusive transporter dependence.\nModel and exposure: Mouse wild-type versus juvenile visceral steatosis model; microdialysis and zero-net-flux analysis.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. | 2003 | https://pubmed.ncbi.nlm.nih.gov/14595704/ | https://doi.org/10.1002/bdd.371 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Mouse wild-type versus juvenile visceral steatosis model; microdialysis and zero-net-flux analysis.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}